Key result
Perioperative dexmedetomidine linked to ~73% lower in-hospital mortality after open-heart surgery.
Why the study?
The study was designed to assess the impact of perioperative dexmedetomidine on the outcomes of open-heart surgery.
Does perioperative dexmedetomidine reduce mortality and complications in patients undergoing open-heart surgery?
Population
350 patients undergoing open-heart surgery at a single cardiology institute
Comparison
Perioperative dexmedetomidine vs no perioperative dexmedetomidine
Design
Retrospective study
Follow-up
30 days
Authors
Loading...
May support perioperative dexmedetomidine in cardiac surgery; leaves open confirmation by randomized trials before practice change.
Cohort (n=350)
No
Does perioperative dexmedetomidine reduce mortality and complications in patients undergoing open-heart surgery?
Absolute Event Rate: 1.22% vs 4.6%
p-value: p=0.008
Perioperative intravenous dexmedetomidine is associated with significantly improved in-hospital and 30-day survival in patients undergoing open-heart surgery.
Zafar et al. (2022) conducted a cohort in Open-heart surgery (n=350). Perioperative dexmedetomidine vs. No perioperative dexmedetomidine was evaluated on In-hospital mortality (p=0.008). Perioperative dexmedetomidine was associated with significantly lower in-hospital mortality compared to no dexmedetomidine (1.22% vs 4.6%, P=0.008) in patients undergoing open-heart surgery.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: